{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-044769","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2024-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.840996+00:00","generated_at":"2026-06-03T22:29:59.247284+00:00","sec_items":["2.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Perspective Therapeutics closes sale of Isoray Cesium-131 business for stock and royalties","bullets":["Sale closed April 12, 2024; Isoray receives 279,516 GT Medical shares (0.5% fully diluted, 0.44% if C-1 warrants exercised) and 4-year tiered royalties.","Royalty on Cesium-131 seed ex-GammaTile: 3% (≤$10M annual net sales), 4% ($10-15M), 5% (≥$15M); GammaTile royalty: 0.5%.","Pro forma 2023 continuing ops: revenue $1.5M, net loss $37.0M (vs reported $46.5M net loss including discontinued ops).","Discontinued Isoray ops 2023: net sales $6.9M, net loss $4.9M plus $4.17M loss on classification as held for sale.","Pro forma balance sheet: total assets $92.8M, stockholders' equity $75.2M after removing Isoray assets/liabilities."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-044769","json":"https://secwatch.observer/filing/0000950170-24-044769.json","markdown":"https://secwatch.observer/filing/0000950170-24-044769.md","text":"https://secwatch.observer/filing/0000950170-24-044769.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000095017024044769/0000950170-24-044769-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000095017024044769/catx-20240412.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T22:29:59.247284+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d82eb86a67af67f72860debdac75d2d7e11b3231","claim":"Perspective Therapeutics, Inc. completed a disposition involving GT Medical Technologies, Inc. for 279,516 shares of GT Medical common stock and certain cash royalty payments for four years based on net sales (closed 2024-04-12).","evidence_excerpt":"the liabilities of Isoray. Pursuant to the terms of, and subject to the conditions specified in, the Asset Purchase Agreement, at the Closing, (i) GT Medical issued to Isoray 279,516 shares of GT Medical’s common stock, par value $0.0001 per share, representing 0.5% of GT Medical’s issued and outstanding capital stock on a fully diluted basis as of the","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/728387/000095017024044769/0000950170-24-044769-index.htm","confidence":0.95,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"GT Medical Technologies, Inc."},{"label":"Consideration","value":"279,516 shares of GT Medical common stock and certain cash royalty payments for four years based on net sales"},{"label":"Closing","value":"2024-04-12"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}